Amgen wins one, loses one in biosimilar battle
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks city manager’s firing won’t hinder economy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ceres faces lawsuit over sale to Land ‘O Lakes
Thousand Oaks-based ag-biotech company Ceres Inc. is facing a lawsuit from shareholders angry about the company’s June 17 sale to Minneapolis-based Land ‘O Lakes. In the lawsuit, which was filed in state court in Los Angeles on July 5, three shareholders allege the company unfairly sold the company to Land ‘O Lakes for $17.6 million. Read More →
Stellar Biotechnologies uses limpets to develop medicine
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen subsidiary discovers rare gene that could reduce heart attack risk
An Amgen subsidiary may have found a rare gene that could drastically reduce the risk of heart attacks in the future. DeCode Genetics, an Iceland-based subsidiary of Thousand Oaks biotech giant Amgen, uncovered a rare and unknown genetic variation in some people that could reduce the risk of heart attacks and lower cholesterol. The variant Read More →
Tri-county entrepreneurs debate value of patents
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies revenues nearly doubled in first quarter
Stellar Biotechnologies revenues nearly doubled but so did the company’s losses during the first quarter, the Port Hueneme biotech company reported May 9. Stellar Biotechnologies makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. The company’s revenues increased from $187,627 during Read More →
